63 results about "Neuroprotective drug" patented technology

An agent for prevention or treatment of diseases involving degeneration or death of nerve cells, characterized by containing a growth hormone secretion promoting substance as an active ingredient, is provided.

Extracts of Lycium barbarum serve as a neuroprotective agent against β-amyloid peptide neurotoxicity which thus permits their use for the treatment of Alzheimer's disease (AD) and for the prevention of neuronal loss in aging against the accumulation of β-amyloid peptide in the brain. Stress kinases (c-Jun N-terminal kinase and double-stranded RNA-dependent protein kinase) are used as a technological platform for screening neuroprotective drugs.

The invention relates to the field of medicine synthesis, and discloses a PSD-95 inhibitor. The PSD-95 inhibitor disclosed by the invention is used for preparing a pharmaceutical composition for treating diseases, and the pharmaceutical composition is used for preparing neuroprotective drugs after ischemic brain injury.

Belonging to the pharmaceutical field, the invention relates to application of nicotinamide phosphoribosyltransferase (NAMPT) in preparation of neuroprotective and rehabilitation drugs. Experiments of the invention show that NAMPT recombinant protein can penetrate the blood-brain barrier to significantly reduce the volume of ischemic brain injury and alleviate white matter injury after ischemic brain injury; the NAMPT recombinant protein can significantly improve long-term behaviors after ischemic brain injury; the NAMPT recombinant protein can raise revascularization related factors to enhance revascularization after brain hypoxia and neuron regeneration after brain hypoxia, and promote post-injury neurologic function reestablishment; and by mediating oligodendrocyte regeneration and alleviating the demyelination effect of local lysolecithin, the NAMPT recombinant protein can promote restoration of white matter after injury and strengthen post-injury neurologic function reestablishment. Results show that the NAMPT recombinant protein plays a long-term neuroprotective role in drugs treating cerebral stroke, traumatic brain injury and multiple sclerosis, and can be used as a neuroprotective drug to treat acute and chronic injury caused by brain stroke.

The present invention discloses a chrysotoxine bibenzyl derivative shown as a formula I. R1 represents C=O, CH2, NH, S=O or a covalent bond; R2 represents alkyl, phenyl, substituted phenyl, benzene ring substituted C1-3 alkyl, C5-C6 cycloalkyl, and a pentabasic or hexahydric unsaturated heterocyclic group containing one or more O, S and N. The invention also discloses a simple and efficient preparation method of the chrysotoxine bibenzyl derivative, and application of the derivative to the preparation of neuroprotective drugs and drugs for treating Alzheimer disease. The chrysotoxine 4-O-substituted bibenzyl derivative has significant protective effect on A beta-induced neuronal apoptosis, and is a potential novel chemical entity for the treatment of AD.

The invention relates to a mixed-element terpene compound and an application thereof. The preparation method comprises the following steps: extracting and separating a Durimane Meroterpenoid compoundfrom fermentation liquor of South China Sea soft coral co-epiphytic fungi Alternanthera sp. The mixed-element terpenoid compound can effectively inhibit excitability of mouse primary cerebral cortex neurons, can relieve the stimulation effect of epilepsy inducer 4-aminopyridine on neurons, and can be used for development of neuroprotective drugs. The invention provides a lead compound and a novelactive skeleton for research and development of neuroprotective drugs, and is beneficial to development and utilization of marine medicinal resources.

The invention discloses a new codonopsis pilosula alkynol compound 1 extracted from codonopsis pilosula, a preparation method thereof, a pharmaceutical composition containing a new codonopsis pilosula alkynol compound and application in a neuroprotective drug, especially senile dementia. Pharmacological experiments show that the compound embodies neuroprotection activity and has good neuroprotection activity in a sodium nitroprusside injury primary neuron model and a glutamic acid-induced primary neuron toxicity model. A structural formula of the compound 1 is as shown in the specification.

The invention provides an application of dicarboxylic acid and ester compounds thereof and in particular relates to an application of the compounds to preparation of neuroprotective drugs. In a chemical formula in the specification, R1 is hydrogen or methyl; R2 is isopropyl or isobutyl; R3 is carboxyl, methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, borneol oxycarbonyl or 5-tetrazole; a is 0 or 1; b is 0 or 1; c is an integer from 1 to 4; b is 0 when a is 0; b is 0 or 1 when a is 1. The compounds have relatively strong protective effects on glutamate-induced neuron damages.

The invention relates to the field of medicine synthesis, and discloses a PSD-95 inhibitor. The PSD-95 inhibitor disclosed by the invention is used for preparing a pharmaceutical composition for treating diseases and an application of the pharmaceutical composition in preparing a neuroprotective drug after ischemic brain injury.

The invention discloses an application of Terreumol A in preparation of a neuroprotective drug and belongs to the field of drugs. The research shows that an apoptosis model of rat chromaffin tumor cell strains PC12 cultured in vitro can be effectively established with the application of 20 mu mol/L of Abeta25-35; Terreumol A can be partially resistant to Abeta25-35 induced PC12 apoptosis and can be further researched and developed to prepare the neuroprotective drug.

The invention discloses application of a composition containing an MG 53 mutant in preparation of neuroprotective drugs. The research results prove that the MG53 mutant has a prominent neuroprotectiveeffect and can cross the blood-brain barrier, thus being applied to prevention or treatment of multiple neurodegenerative diseases such as ischemic stroke, brain atrophy, senile dementia, multiple system atrophy, brain atrophy, motor neuron diseases, ataxia telangiectasia, spinal muscular atrophy and optic atrophy.

The invention discloses application of 4-methoxybenzyl alcohol in preparation of neuroprotective drugs. 4-methoxybenzyl alcohol may reduce injury of primary cortical neurons OGD/Rep of fetal rats and neuron morphological structure injury and increase survival rate of OGD/Rep injured cortex; the release of OGD/Rep injured cortical neuron NO is reduced, activity of SOD (superoxide dismutase) in cells is improved, generation of MDA (methane dicarboxylic aldehyde) is inhibited, apoptosis of nerve cells may be inhibited through significant up-regulation of Bcl-2 protein expression and down-regulation of Bax protein and Caspase-3 protein expression, neuroprotective effect is good, neuroprotective drugs may be produced, and nerve injury is reduced; in addition, the 4-methoxybenzyl alcohol may promote synapse growth of nerve cells, up-regulate synapse growth related proteins, promote repair of the nerve cells and treat nerve injury.

The invention discloses an application of a depsidone compound in preparation of neuroprotective drugs. The depsidone compound is proved to significantly improve the survival rate of cerebral cortex nerve cells, and has an extremely significant reversal effect on MPP+ induced cerebral cortex nerve cell damage; in addition, the depsidone compound is efficient and free of toxic and side effects on patients. Therefore, the depsidone compound can be applied to preparation of the neuroprotective drugs, preparation of drugs for relieving/reversing MPP+ induced nerve cell damage and preparation of drugs for preventing/treating neurodegenerative diseases. A new technology, a new method and a new means are provided for efficiently treating neurodegenerative diseases, especially Parkinson's disease,and a good application prospect and a wide development space are achieved.